Array biopharma

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500

sepan
Forum veteraan
Forum veteraan
Berichten: 1268
Lid geworden op: 08 aug 2012 08:08
waarderingen: 605
Contacteer:

Re: Array biopharma

Bericht door sepan » 21 mei 2019 16:15

Array BioPharma's colorectal cancer combo treatment meets main goals
14:00 (21/05) - Bron: Reuters
By Saumya Joseph
May 21 (Reuters) - Array BioPharma Inc's cocktail
of three therapies helped patients with a type of colorectal
cancer live longer than those on standard treatment, according
to interim results of a late-stage study on Tuesday.
The combination therapy, comprising Array's Braftovi and
Mektovi and Eli Lilly and Co's LLY.N Erbitux, helped half the
patients enrolled in the study survive nine months.
This was in comparison to the standard regimen of Erbitux
and chemotherapy irinotecan, which showed a median overall
survival of 5.4 months in patients.
Array's combination also helped reduce the risk of death
from colorectal cancer by 48% compared to the standard of care
in patients, with a gene mutation known as BRAF V600E, whose
cancer had progressed after one or two other therapies.
The mutation occurs in up to 15% of metastatic colorectal
cancer patients, and there are no FDA-approved treatments for
the condition, according to the company.
Colorectal cancer is the third leading cause of
cancer-related deaths in men and women, and about 145,600 new
cases of colon or rectal cancer are expected in the United
States in 2019, according to the American Cancer Society.
The company said it is testing the combination as a
potential first-line treatment for colorectal cancer patients
with the BRAF V600E mutation in a separate study.
"We've seen that in earlier lines of patients there appears
to be more tumor shrinkage ... the goal ultimately is to treat
patients as early as possible," Chief Executive Officer Ron
Squarer told Reuters.
In the latest study, Array also tested a double-combination
version of the therapy, which helped reduce the risk of death by
40%, with a median overall survival rate of 8.4 months.
Both combinations were generally well tolerated with no
unexpected toxicities. The company said it expects to submit the
data for marketing approval in the second half of 2019.
Array's Braftovi and Mektovi received FDA approval last year
for treating a deadly form of skin cancer.

(Reporting by Saumya Sibi Joseph in Bengaluru; Editing by
Shinjini Ganguli)
((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 2290; Reuters Messaging:
saumya.joseph.thomsonreuters.com@reuters.net))



powered by Surfing Waves

sepan
Forum veteraan
Forum veteraan
Berichten: 1268
Lid geworden op: 08 aug 2012 08:08
waarderingen: 605
Contacteer:

Re: Array biopharma

Bericht door sepan » 21 mei 2019 16:16

15 % omhoog al vandaag...laat de overname maar komen :lol:

sepan
Forum veteraan
Forum veteraan
Berichten: 1268
Lid geworden op: 08 aug 2012 08:08
waarderingen: 605
Contacteer:

Re: Array biopharma

Bericht door sepan » 21 mei 2019 16:29


rouches
Forum actieveling
Forum actieveling
Berichten: 564
Lid geworden op: 02 jan 2012 23:25
waarderingen: 138
Contacteer:

Re: Array biopharma

Bericht door rouches » 17 jun 2019 13:16

Tis zover :up: :up: :up:
In portefeuille: Pharming, ACPH,TNG, CLSD, EVOK, OXUR, IVA

sepan
Forum veteraan
Forum veteraan
Berichten: 1268
Lid geworden op: 08 aug 2012 08:08
waarderingen: 605
Contacteer:

Re: Array biopharma

Bericht door sepan » 17 jun 2019 17:15

Pfizer neemt Array Biopharma over voor 48 $ per aandeel, premie van 62 €...

Yes 2de dikke overname na Tigenix !!!

Met dank aan Believer die me de weg wees naar deze kanjer! :)
Bid deal :clap: :clap:
believer liked last!

sepan
Forum veteraan
Forum veteraan
Berichten: 1268
Lid geworden op: 08 aug 2012 08:08
waarderingen: 605
Contacteer:

Re: Array biopharma

Bericht door sepan » 17 jun 2019 19:25

sepan schreef:Pfizer neemt Array Biopharma over voor 48 $ per aandeel, premie van 62 €%...

Yes 2de dikke overname na Tigenix !!!

Met dank aan Believer die me de weg wees naar deze kanjer! :)
Bid deal :clap: :clap:
Premie van 62 % natuurlijk ipv € :lol:

Deelnemen aan het forum + meer functies?

Discussieer met duizenden beleggers, minder
advertenties, ideaal voor smartphone, betere
gebruikservaring en gratis abonneren op favoriete
onderwerpen. 
Registreer binnen enkele tellen



Plaats reactie